Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Worldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter
Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows Non-GAAP adjusted operating expense guidance to $380 to $395…
